Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair...

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Microsatellite instability (MSI) is a tumor phenotype resulting from a deficient DNA mismatch repair system (dMMR).
• MSI/dMMR is found in 5% of metastatic and 10-18% of localized colorectal cancer (CRC).
• This phenotype is linked to high tumor mutational burden and immunogenic neoantigens, making it a key predictive biomarker for immune checkpoint inhibitors (ICIs).

Purpose of the Study:

• To provide a comprehensive literature review on the efficacy of ICIs in patients with MSI/dMMR metastatic colorectal cancer (mCRC).
• To focus on recent advancements in the first-line metastatic setting for MSI/dMMR mCRC.
• To discuss current and future challenges in immuno-oncology for this patient population.

Main Methods:

• Literature review of studies on MSI/dMMR status and ICI efficacy in mCRC.
• Analysis of data concerning first-line treatment strategies.
• Identification and discussion of challenges in immuno-oncology for MSI/dMMR mCRC.

Main Results:

• MSI/dMMR is a significant predictive biomarker for ICI efficacy in mCRC.
• Emerging data suggests positive outcomes for ICIs in the first-line metastatic setting.
• Specific challenges remain in optimizing and expanding immunotherapy approaches.

Conclusions:

• ICIs represent a promising therapeutic strategy for patients with MSI/dMMR mCRC.
• Further research is needed to address current challenges and optimize first-line treatment.
• Immuno-oncology holds significant potential for improving outcomes in this subset of colorectal cancer patients.